Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clinical Pharmacology

Conditions

Clinical Pharmacology

Trial Timeline

Apr 19, 2010 → Jun 7, 2010

About Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil

Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil is a phase 1 stage product being developed by Bayer for Clinical Pharmacology. The current trial status is completed. This product is registered under clinical trial identifier NCT03136666. Target conditions include Clinical Pharmacology.

What happened to similar drugs?

1 of 4 similar drugs in Clinical Pharmacology were approved

Approved (1) Terminated (1) Active (3)
PosaconazoleMerckApproved
🔄Lecanemab + PlaceboEisaiPhase 3
🔄Rebif®MerckPhase 3
🔄Cannabidiol (CBD) + PlaceboJazz PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03136666Phase 1Completed